{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:50:31Z","timestamp":1793875831823,"version":"4.7.0"},"reference-count":75,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Research Foundation","award":["DFG Si 1983\/4-1"],"award-info":[{"award-number":["DFG Si 1983\/4-1"]}]},{"name":"German Research Foundation","award":["MU 2864\/1-3"],"award-info":[{"award-number":["MU 2864\/1-3"]}]},{"name":"German Research Foundation","award":["MU 2864\/3-1"],"award-info":[{"award-number":["MU 2864\/3-1"]}]},{"name":"German Research Foundation","award":["403224013"],"award-info":[{"award-number":["403224013"]}]},{"name":"German Research Foundation","award":["DFG Si 1983\/4-1"],"award-info":[{"award-number":["DFG Si 1983\/4-1"]}]},{"name":"German Research Foundation","award":["MU 2864\/1-3"],"award-info":[{"award-number":["MU 2864\/1-3"]}]},{"name":"German Research Foundation","award":["MU 2864\/3-1"],"award-info":[{"award-number":["MU 2864\/3-1"]}]},{"name":"German Research Foundation","award":["403224013"],"award-info":[{"award-number":["403224013"]}]},{"name":"German Research Foundation","award":["DFG Si 1983\/4-1"],"award-info":[{"award-number":["DFG Si 1983\/4-1"]}]},{"name":"German Research Foundation","award":["MU 2864\/1-3"],"award-info":[{"award-number":["MU 2864\/1-3"]}]},{"name":"German Research Foundation","award":["MU 2864\/3-1"],"award-info":[{"award-number":["MU 2864\/3-1"]}]},{"name":"German Research Foundation","award":["403224013"],"award-info":[{"award-number":["403224013"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The soluble urokinase-type plasminogen activator receptor (suPAR) has evolved as a useful biomarker for different entities of chronic liver disease. However, its role in patients with primary sclerosing cholangitis (PSC) is obscure. We analyzed plasma levels of suPAR in 84 patients with PSC and compared them to 68 patients with inflammatory bowel disease (IBD) without PSC and to 40 healthy controls. Results are correlated with clinical records. suPAR concentrations were elevated in patients with PSC compared to patients with IBD only and to healthy controls (p &lt; 0.001). Elevated suPAR levels were associated with the presence of liver cirrhosis (p &lt; 0.001) and signs of portal hypertension (p &lt; 0.001). suPAR revealed a high accuracy for the discrimination of the presence of liver cirrhosis comparable to previously validated noninvasive fibrosis markers (area under the curve (AUC) 0.802 (95%CI: 0.702\u20130.902)). Further, we demonstrated that suPAR levels may indicate the presence of acute cholangitis episodes (p &lt; 0.001). Finally, despite the high proportion of PSC patients with IBD, presence of IBD and its disease activity did not influence circulating suPAR levels. suPAR represents a previously unrecognized biomarker for diagnosis and liver cirrhosis detection in patients with PSC. However, it does not appear to be confounded by intestinal inflammation in the context of IBD.<\/jats:p>","DOI":"10.3390\/jcm11092479","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T22:20:06Z","timestamp":1651184406000},"page":"2479","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-737X","authenticated-orcid":false,"given":"Burcin","family":"\u00d6zdirik","sequence":"first","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Charit\u00e9 Universit\u00e4tsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"},{"name":"Berlin Institute of Health, 10178 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Maibier","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Charit\u00e9 Universit\u00e4tsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Scherf","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Charit\u00e9 Universit\u00e4tsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jule Marie","family":"Nicklaus","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Charit\u00e9 Universit\u00e4tsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Frohme","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Charit\u00e9 Universit\u00e4tsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2662-6127","authenticated-orcid":false,"given":"Tobias","family":"Puengel","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Charit\u00e9 Universit\u00e4tsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"},{"name":"Berlin Institute of Health, 10178 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Meyer zum B\u00fcschenfelde","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, 13353 Berlin, Germany"},{"name":"Labor Berlin\u2014Charit\u00e9 Vivantes GmbH, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-0226","authenticated-orcid":false,"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Charit\u00e9 Universit\u00e4tsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3426-5421","authenticated-orcid":false,"given":"Tobias","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Charit\u00e9 Universit\u00e4tsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sigal","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Campus Virchow Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM), Charit\u00e9 Universit\u00e4tsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany"},{"name":"Berlin Institute for Medical Systems Biology (BIMSB), Max Delbr\u00fcck Center for Molecular Medicine, 10115 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMra1506330","article-title":"Primary Sclerosing Cholangitis","volume":"375","author":"Lazaridis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2013.06.052","article-title":"Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management","volume":"145","author":"Eaton","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","author":"Hirschfield","year":"2013","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/apt.12581","article-title":"Review article: Controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"39","author":"Karlsen","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/apt.12979","article-title":"Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis","volume":"40","author":"Rupp","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/liv.13110","article-title":"Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: Evaluation of prognostic value","volume":"36","author":"Wang","year":"2016","journal-title":"Liver Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00535-020-01663-1","article-title":"An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort","volume":"55","author":"Bakhshi","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100328","DOI":"10.1016\/j.jhepr.2021.100328","article-title":"Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF","volume":"3","author":"Fossdal","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MOG.0000000000000163","article-title":"Biomarkers for disease progression of primary sclerosing cholangitis","volume":"31","author":"Beuers","year":"2015","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2020.07.032","article-title":"Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients with Primary Sclerosing Cholangitis","volume":"19","author":"Trivedi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1155\/2009\/504294","article-title":"suPAR: The molecular crystal ball","volume":"27","author":"Macho","year":"2009","journal-title":"Dis. Markers"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nm1696","article-title":"Modification of kidney barrier function by the urokinase receptor","volume":"14","author":"Wei","year":"2008","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.2741\/3392","article-title":"Multiple activities of a multifaceted receptor: Roles of cleaved and soluble uPAR","volume":"14","author":"Montuori","year":"2009","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-59349-9_1","article-title":"The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA\/uPA-receptor interaction","volume":"162","author":"Guthaus","year":"2003","journal-title":"Recent Results Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrm977","article-title":"uPAR: A versatile signalling orchestrator","volume":"3","author":"Blasi","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/368419a0","article-title":"Physiological consequences of loss of plasminogen activator gene function in mice","volume":"368","author":"Carmeliet","year":"1994","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1172\/JCI119148","article-title":"Impaired arterial neointima formation in mice with disruption of the plasminogen gene","volume":"99","author":"Carmeliet","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1478-3231.2011.02665.x","article-title":"Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis","volume":"32","author":"Zimmermann","year":"2012","journal-title":"Liver Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00001813-200106000-00001","article-title":"The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer","volume":"12","author":"Mazar","year":"2001","journal-title":"Anticancer Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"39481","DOI":"10.1038\/srep39481","article-title":"Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: A systematic review and meta-analysis","volume":"6","author":"Ni","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Donadello, K., Scolletta, S., Covajes, C., and Vincent, J.L. (2012). suPAR as a prognostic biomarker in sepsis. BMC Med., 10.","DOI":"10.1186\/1741-7015-10-2"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa1911481","article-title":"Soluble Urokinase Receptor and Acute Kidney Injury","volume":"382","author":"Hayek","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40560-019-0381-5","article-title":"Neutrophils are a main source of circulating suPAR predicting outcome in critical illness","volume":"7","author":"Gussen","year":"2019","journal-title":"J. Intensive Care"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"\u00d6zdirik, B., Stueven, A., Knorr, J., Geisler, L., Mohr, R., Demir, M., Hellberg, T., Loosen, S.H., Benz, F., and Wiedenmann, B. (2020). Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations are Elevated in Patients with Neuroendocrine Malignancies. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061647"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.thromres.2008.06.013","article-title":"Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B","volume":"123","author":"Zhou","year":"2009","journal-title":"Thromb. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MCG.0b013e31822da19d","article-title":"Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection","volume":"46","author":"Berres","year":"2012","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/joim.12054","article-title":"Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality","volume":"274","author":"Zimmermann","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/cld.850","article-title":"Soluble Urokinase Receptor and Liver Disease","volume":"14","author":"Wei","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/liv.12512","article-title":"Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure","volume":"34","author":"Koch","year":"2014","journal-title":"Liver Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG Clinical Guideline: Primary Sclerosing Cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"European Association for The Study of the Liver (2009). EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J. Hepatol., 51, 237\u2013267.","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis-A comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jhbp.512","article-title":"Tokyo Guidelines 2018: Diagnostic criteria and severity grading of acute cholangitis (with videos)","volume":"25","author":"Kiriyama","year":"2018","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1055\/s-2006-925257","article-title":"Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis","volume":"38","author":"Tischendorf","year":"2006","journal-title":"Endoscopy"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0168-8278(01)00251-3","article-title":"Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: Outcome after endoscopic treatment","volume":"36","author":"Stiehl","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, and Clinical Practice Guideline Panel (2021). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update. J. Hepatol., 75, 659\u2013689.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","author":"Corpechot","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hep.21835","article-title":"Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: A systematic review","volume":"46","author":"Shaheen","year":"2007","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A revised natural history model for primary sclerosing cholangitis","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clin. Proc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","article-title":"A novel prognostic model for transplant-free survival in primary sclerosing cholangitis","volume":"67","author":"Wang","year":"2018","journal-title":"Gut"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-2036.2005.02691.x","article-title":"Systematic review: The model for end-stage liver disease--should it replace Child-Pugh\u2019s classification for assessing prognosis in cirrhosis?","volume":"22","author":"Cholongitas","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_46","first-page":"1","article-title":"Surgery and portal hypertension","volume":"1","author":"Child","year":"1964","journal-title":"Major Probl. Clin. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br. J. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJM199109263251306","article-title":"Inflammatory bowel disease (1)","volume":"325","author":"Podolsky","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJM199110033251406","article-title":"Inflammatory bowel disease (2)","volume":"325","author":"Podolsky","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory bowel disease","volume":"347","author":"Podolsky","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_51","first-page":"1070","article-title":"An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index","volume":"20","author":"Bewtra","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01.MIB.0000215091.77492.2a","article-title":"Predicting the Crohn\u2019s disease activity index from the Harvey-Bradshaw Index","volume":"12","author":"Best","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2796.2010.02252.x","article-title":"Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population","volume":"268","author":"Andersen","year":"2010","journal-title":"J. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.atherosclerosis.2011.10.039","article-title":"Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malm\u00f6 Diet and Cancer Study","volume":"220","author":"Persson","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cjca.2015.03.023","article-title":"suPAR: A New Biomarker for Cardiovascular Disease?","volume":"31","author":"Hodges","year":"2015","journal-title":"Can. J. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1111\/j.1572-0241.2000.03292.x","article-title":"Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis","volume":"95","author":"Saarinen","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"104231","DOI":"10.1016\/j.ejmg.2021.104231","article-title":"Present and future role of endoscopic retrograde cholangiography in primary sclerosing cholangitis","volume":"64","author":"Waldthaler","year":"2021","journal-title":"Eur. J. Med. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1055\/s-0043-107029","article-title":"Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline","volume":"49","author":"Aabakken","year":"2017","journal-title":"Endoscopy"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jhep.2009.01.023","article-title":"Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis","volume":"51","author":"Rudolph","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/MEG.0b013e3283554bbf","article-title":"Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: A 25-year single-centre experience","volume":"24","author":"Chapman","year":"2012","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"100080","DOI":"10.1016\/j.jhepr.2020.100080","article-title":"Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer","volume":"2","author":"Loosen","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.trsl.2014.09.007","article-title":"Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease","volume":"165","author":"Martinsson","year":"2015","journal-title":"Transl. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/jgh.12639","article-title":"Serum soluble urokinase plasminogen activator receptor in alcoholics: Relation to liver disease severity, fibrogenesis, and alcohol use","volume":"29","author":"Tuomi","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/jhep.2000.16602","article-title":"Practices of liver biopsy in France: Results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF)","volume":"32","author":"Cadranel","year":"2000","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-8278(00)80185-3","article-title":"Enhanced monocyte activation and hepatotoxicity in response to endotoxin in portal hypertension","volume":"32","author":"Pizcueta","year":"2000","journal-title":"J. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1084\/jem.188.6.1029","article-title":"Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo","volume":"188","author":"May","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2249.2008.03606.x","article-title":"Immunomodulatory effects of plasminogen activators on hepatic fibrogenesis","volume":"152","author":"Higazi","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"ref_68","first-page":"717","article-title":"Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance","volume":"79","author":"Sier","year":"1999","journal-title":"Lab. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/172460080101600402","article-title":"Soluble urokinase plasminogen activator receptor measurements: Influence of sample handling","volume":"16","author":"Riisbro","year":"2001","journal-title":"Int. J. Biol. Markers"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1373\/clinchem.2006.067595","article-title":"Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology","volume":"52","author":"Kofoed","year":"2006","journal-title":"Clin. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/cc10037","article-title":"Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients","volume":"15","author":"Koch","year":"2011","journal-title":"Crit. Care"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/00365521.2012.699549","article-title":"Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease","volume":"47","author":"Kolho","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3109\/00365521.2010.539253","article-title":"Blood chemistry markers for evaluation of inflammatory activity in Crohn\u2019s disease during infliximab therapy","volume":"46","author":"Theodorsson","year":"2011","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/gut.2007.146357","article-title":"C-reactive protein: A predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study","volume":"57","author":"Henriksen","year":"2008","journal-title":"Gut"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/gut.2005.069476","article-title":"Laboratory markers in IBD: Useful, magic, or unnecessary toys?","volume":"55","author":"Vermeire","year":"2006","journal-title":"Gut"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/9\/2479\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:03:07Z","timestamp":1760137387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/9\/2479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":75,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["jcm11092479"],"URL":"https:\/\/doi.org\/10.3390\/jcm11092479","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]}}}